Navigation Links
Endo and Metamark Announce Sale of HealthTronics Laboratory Solutions

MALVERN, Pa. and CAMBRIDGE, Mass., Aug. 12, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that its wholly owned subsidiary, HealthTronics, Inc. has entered into a definitive agreement to sell its anatomical pathology business, HealthTronics Laboratory Solutions, Inc., ("HLS") to Metamark Genetics, Inc. ("Metamark") for an undisclosed amount.   As previously announced Endo Health Solutions is pursuing strategic alternatives for HealthTronics, Inc. and believes the sale of HLS creates progress in this process.  

Metamark is at the leading edge of research in cancer prognosis, which is a critical tool in determining appropriate cancer therapy. In the age of personalized medicine, particularly in oncology, Metamark's proprietary multiplex proteomic platform has the potential to reshape the landscape in cancer diagnosis and therapy.

HLS provides anatomical pathology services primarily to the urology community. The HLS pathology labs are located in Georgia and Pennsylvania and provide laboratory and diagnostic services to urologists throughout the U.S., with client practices in 41 states.  In addition, HLS manages pathology laboratories for physician practice groups, provides administrative services to in-office pathology labs for practice groups, and provides pathology services to physicians.

"HLS is a recognized national reference lab providing specialized pathology services to the urology community with a reputation for quality," said Shawn M. Marcell, president and CEO of Metamark Genetics. "We believe joining forces with HLS will be instrumental to our success as we commercialize ProMark™, Metamark's novel prostate cancer test."

Kelly Huang, PhD, President of HealthTronics, stated "Metamark has strong ambitions for growth, shares our commitment to improved patient outcomes, and is dedicated to continue to serve the needs of urologists and the patients for which they care."

About HealthTronics

HealthTronics has been a national provider of urological and interventional oncology services and products for more than 20 years. Headquartered in Austin, Texas, with anatomical pathology laboratories in three states, the company provides the most advanced technology and premiere support systems to urologists, interventional radiologists, hospitals, surgery centers and clinics across the United States. HealthTronics is an operating company of Endo Health Solutions Inc.

About Endo

Endo Health Solutions Inc. (Endo) is a U.S.-based specialty healthcare company with four distinct business segments that are focused on branded and generic pharmaceuticals, devices and services, each providing quality products to our customers while improving the lives of patients.  Through our operating companies – AMS, Endo Pharmaceuticals, HealthTronics and Qualitest – Endo is dedicated to finding solutions for the unmet needs of patients. Learn more at

About Metamark

Metamark Genetics, Inc. ("Metamark") is a privately held biotechnology company founded in 2007 to develop new function-based prognostic and diagnostic tests aimed at improving cancer care.  The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon and breast cancers. During 2013, Metamark plans to commercialize ProMark™ – its lead prostate cancer prognostic test – through its Cambridge, MA CLIA-certified laboratory.  For more information, please visit the company's Website at  Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.

SOURCE Endo Health Solutions
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Metamark Genetics Board of Directors Appoints Shawn M. Marcell President and Chief Executive Officer
2. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
3. PipelineRx Announces Telepharmacy Contract with GNYHA Services
4. ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
5. Valeant Pharmaceuticals Announces Continuance
6. PatientStream Announces Industry Top Performer, Tom McLaren, to Lead an Exclusive Education Webinar on Surgical Efficiency to 300+ hospitals nationwide.
7. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
8. Northwest Biotherapeutics Announces Registered Direct Offering
9. PDL BioPharma Announces Second Quarter 2013 Financial Results
10. Echo Therapeutics Announces Second Quarter 2013 Financial Results
11. Alere Announces Preliminary Results Of Voting At Annual Meeting
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... and wellness consultation, has collaborated with Women’s Web – an online resource ... on topics on mental and emotional well-being relationship, life balance, stress, professional ...
Breaking Medicine News(10 mins):